Pfizer Is The Large Cap Biotech Play - Cramer's Lightning Round (1/11/16)

|
Includes: BPL, DVN, EPR, GRPN, MRK, PFE, TRN, XPO
by: SA Editor Mohit Manghnani

Summary

Stay away from Groupon.

MLP and pipeline companies have a lot of pain left.

EPR Properties has a good yield.

Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, January 11.

Bullish Call:

EPR Properties (NYSE:EPR): The company has the casino angle and a 6.3% yield. That's the stock people should buy.

Bearish Calls:

Groupon (NASDAQ:GRPN): It's still early to buy the stock.

Buckeye Partners (NYSE:BPL): Cramer doesn't recommend owning an MLP or a pipeline company.

XPO Logistics (NYSEMKT:XPO): This market does not like companies that used to buy other companies. They don't like the high-yielding market either.

Merck (NYSE:MRK): Pfizer is the large cap biotech play in the current environment.

Trinity Industries (NYSE:TRN): Anything connected to rails is in a bear market.

Devon Energy (NYSE:DVN): Cramer doesn't want to touch Devon till it reaches a 5% yield, as a lot of 5% yielders are already down.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

Jim Cramer's Action Alerts PLUS: Check out Cramer's multi-million dollar charitable trust portfolio and uncover the stocks he thinks could be HUGE winners. Start your FREE 14-day trial now!

Get Cramer's Picks by email - it's free and takes only a few seconds to sign up.